SOURCE: Global Equity Reporter

May 31, 2011 09:16 ET

BioTech Insight Demonstrates Change Ahead -- Report on Fibrocell Science and RegeneRx Biopharmaceuticals, Inc.

BEIJING--(Marketwire - May 31, 2011) - Today, announced its research report highlighting Fibrocell Science, Inc. (OTCBB: FCSC) and RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX). Full report download is available at

Biotech is enabling creation of new drugs at a faster pace than the traditional pharmaceutical model and some believe that after a decade of mediocre performance it is approaching an inflection point. Companies are much more conducive to focusing on productivity and the sector is showing signs of being back to top growth by 2013 due to the opportunity emerging markets have created.

Global Equity is reporting on Fibrocell Science for its focus as an aesthetic and therapeutic development stage biotechnology company focused on developing novel skin and tissue rejuvenation products. The Company's clinical development product candidates are designed to improve the appearance of skin injured by the effects of aging, sun exposure, acne and burn scars with a patient's own, or autologous, fibroblast cells produced by its Fibrocell process. The Company's clinical development programs encompass both aesthetic and therapeutic indication. The full report and profile on Fibrocell Science, Inc. (OTCBB: FCSC) is available here:

Global Equity Reporter brings RegeneRx Biopharmaceuticals to light for its focus as a biopharmaceutical company focused on the discovery and development of molecules to promote tissue and organ protection, repair and regeneration. As of December 31, 2009, the Company had formulated three product candidates based on Thymosin beta 4 (Tb4), a 43-amino acid peptide, which are in clinical development. RGN-137 is a topically applied for chronic dermal wounds and reduction of scar tissue. The full report and profile on RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) is available here:

About Global Equity Reporter
Global Equity Reporter is a premier source for microcap research -- providing a wide range of due diligence and investment insight on stocks all over the market Global Equity Reporter's primary focus is to alert our valued subscribers to small cap and microcap companies poised for explosive movement in the market. As every investor knows, timing in the market is critical, and that's where Global Equity Reporter delivers. We report potential market opportunity to our members before the same situation grows to become strong market momentum, enabling our members to see strong market growth by delivering information before the crowd.

Contact Information